Pharmicell (005690) - Total Liabilities

Latest as of September 2025: ₩19.60 Billion KRW ≈ $13.28 Million USD

Based on the latest financial reports, Pharmicell (005690) has total liabilities worth ₩19.60 Billion KRW (≈ $13.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Pharmicell (005690) net asset momentum to track the company's year-over-year net asset growth rate.

Pharmicell - Total Liabilities Trend (2010–2024)

This chart illustrates how Pharmicell's total liabilities have evolved over time, based on quarterly financial data. See 005690 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Pharmicell Competitors by Total Liabilities

The table below lists competitors of Pharmicell ranked by their total liabilities.

Company	Country	Total Liabilities
Ashiana Housing Limited NSE:ASHIANA	India	Rs32.50 Billion
Malteries Franco-Belges Société Anonyme PA:MALT	France	€30.52 Million
Tianjin Realty Development Group Co Ltd SHG:600322	China	CN¥143.24 Million
African Gold Ltd AU:A1G	Australia	AU$3.23 Million
Colony Bankcorp Inc. NYSE:CBAN	USA	$3.34 Billion
Dynasty Ceramic Public Company Limited BK:DCC	Thailand	฿3.39 Billion
V.S.T Tillers Tractors Limited NSE:VSTTILLERS	India	Rs2.50 Billion
Kalyani Steels Limited NSE:KSL	India	Rs8.52 Billion

Liability Composition Analysis (2010–2024)

This chart breaks down Pharmicell's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pharmicell stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmicell's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmicell (2010–2024)

The table below shows the annual total liabilities of Pharmicell from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩12.83 Billion ≈ $8.69 Million	+5.80%
2023-12-31	₩12.12 Billion ≈ $8.21 Million	-63.25%
2022-12-31	₩32.98 Billion ≈ $22.35 Million	+8.28%
2021-12-31	₩30.46 Billion ≈ $20.64 Million	+141.01%
2020-12-31	₩12.64 Billion ≈ $8.57 Million	+7.60%
2019-12-31	₩11.75 Billion ≈ $7.96 Million	+1.03%
2018-12-31	₩11.63 Billion ≈ $7.88 Million	+49.86%
2017-12-31	₩7.76 Billion ≈ $5.26 Million	+5.44%
2016-12-31	₩7.36 Billion ≈ $4.99 Million	-56.58%
2013-12-31	₩16.95 Billion ≈ $11.49 Million	-51.36%
2012-12-31	₩34.84 Billion ≈ $23.61 Million	+90.07%
2011-12-31	₩18.33 Billion ≈ $12.42 Million	-7.59%
2010-12-31	₩19.84 Billion ≈ $13.45 Million	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$418.84 Million

₩618.04 Billion KRW

Market Cap Rank

#13032 Global

#356 in Korea

Share Price

₩10300.00

Change (1 day)

+1.68%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00